Citigroup Inc Bellus Health Inc. Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$7.14 - $8.53 $731,507 - $873,915	102,452 Added 7489.18%	103,820 $747,000
Q4 2022 Feb 09, 2023	BUY	$8.22 - $10.76 $854 - $1,119	104 Added 8.23%	1,368 $11,000
Q3 2022 Nov 10, 2022	SELL	$8.95 - $12.0 $86,403 - $115,848	-9,654 Reduced 88.42%	1,264 $13,000
Q2 2022 Aug 10, 2022	BUY	$6.46 - $10.02 $55,601 - $86,242	8,607 Added 372.44%	10,918 $100,000
Q1 2022 May 12, 2022	SELL	$5.56 - $7.99 $478 - $687	-86 Reduced 3.59%	2,311 $16,000
Q4 2021 Feb 10, 2022	BUY	$5.26 - $8.3 $12,608 - $19,895	2,397 New	2,397 $19,000

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.